Would you give abiraterone in the post-prostatectomy setting to patients with positive nodes detected at surgery?

This clinical scenario of N1 but resected disease post-RP represents an area where there is not sufficient evidence to recommend abiraterone or any potent AR inhibitor. While there is evidence to support ADT in this adjuvant setting for N1 resected patients based on the older Messing ECOG trial, similar trials have not been conducted testing the early use of adjuvant abiraterone or other AR inhibitors in these patients. For patients with still visible N1 or node only M1 disease radiographically ...